New tetracycline drugs take on superbugs in Real-World trial

NCT ID NCT06990126

ENROLLING_BY_INVITATION Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This real-world study is testing two neotetracycline drugs, eravacycline and tigecycline, in 300 adults with drug-resistant Gram-negative bacterial infections. Researchers will track how well the drugs clear the infection and monitor for side effects. The goal is to see if these antibiotics work effectively outside of strict clinical trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neotetracycline drugs (eravacycline and tigecycline)
What this could lead to: If successful, this study could confirm that neotetracycline drugs are effective and safe for treating hard-to-treat Gram-negative bacterial infections in real-world settings.
What could go wrong: This is an observational, real-world study, not a controlled trial, so results may be less definitive. The study is also relatively small and may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL EFFICACY AND SAFETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL EFFICACY AND SAFETY

Contacts and locations

Locations

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.